Ursodeoxycholic acid (English Wikipedia)

Analysis of information sources in references of the Wikipedia article "Ursodeoxycholic acid" in English language version.

refsWebsite

Global rank English rank

52nih.gov

4^th place

35doi.org

2^nd place

10semanticscholar.org

11^th place

8^th place

5web.archive.org

1^st place

4fda.gov

447^th place

338^th place

1drugs.com

399^th place

333^rd place

1tga.gov.au

3,984^th place

2,622^nd place

1canada.ca

1,712^th place

1,063^rd place

1hpfb-dgpsa.ca

low place

1medicines.org.uk

3,823^rd place

2,387^th place

1who.int

195^th place

302^nd place

1axcan.com

low place

1handle.net

102^nd place

76^th place

1fishersci.com

low place

1harvard.edu

18^th place

17^th place

1sukl.cz

low place

axcan.com (Global: low place; English: low place)

"Urso package insert" (PDF). Birmingham, AL: Axcan Pharma U.S. January 2000. Archived from the original (PDF) on 17 October 2006. Retrieved 25 April 2009.

canada.ca (Global: 1,712^th place; English: 1,063^rd place)

health-products.canada.ca

"Product information". Health Canada. 3 August 2000. Retrieved 3 March 2024.

doi.org (Global: 2^nd place; English: 2^nd place)

Hagey LR, Crombie DL, Espinosa E, Carey MC, Igimi H, Hofmann AF (November 1993). "Ursodeoxycholic acid in the Ursidae: biliary bile acids of bears, pandas, and related carnivores". Journal of Lipid Research. 34 (11): 1911–1917. doi:10.1016/S0022-2275(20)35109-9. PMID 8263415.
Hofmann AF (September 1989). "Medical dissolution of gallstones by oral bile acid therapy". American Journal of Surgery. 158 (3): 198–204. doi:10.1016/0002-9610(89)90252-3. PMID 2672842.
Jüngst C, Kullak-Ublick GA, Jüngst D (2006). "Gallstone disease: Microlithiasis and sludge". Best Practice & Research. Clinical Gastroenterology. 20 (6): 1053–1062. doi:10.1016/j.bpg.2006.03.007. PMID 17127187.
Magouliotis DE, Tasiopoulou VS, Svokos AA, Svokos KA, Chatedaki C, Sioka E, et al. (November 2017). "Ursodeoxycholic Acid in the Prevention of Gallstone Formation After Bariatric Surgery: an Updated Systematic Review and Meta-analysis". Obesity Surgery. 27 (11): 3021–3030. doi:10.1007/s11695-017-2924-y. PMID 28889240. S2CID 4622165.
Poupon RE, Balkau B, Eschwège E, Poupon R (May 1991). "A multicenter, controlled trial of ursodiol for the treatment of primary biliary cirrhosis. UDCA-PBC Study Group". The New England Journal of Medicine. 324 (22): 1548–1554. doi:10.1056/NEJM199105303242204. PMID 1674105.
Goulis J, Leandro G, Burroughs AK (September 1999). "Randomised controlled trials of ursodeoxycholic-acid therapy for primary biliary cirrhosis: a meta-analysis". Lancet. 354 (9184): 1053–1060. doi:10.1016/S0140-6736(98)11293-X. PMID 10509495. S2CID 25562983.
Shi J, Wu C, Lin Y, Chen YX, Zhu L, Xie WF (July 2006). "Long-term effects of mid-dose ursodeoxycholic acid in primary biliary cirrhosis: a meta-analysis of randomized controlled trials". The American Journal of Gastroenterology. 101 (7): 1529–1538. doi:10.1111/j.1572-0241.2006.00634.x. PMID 16863557. S2CID 32076958.
Rudic JS, Poropat G, Krstic MN, Bjelakovic G, Gluud C (December 2012). "Ursodeoxycholic acid for primary biliary cirrhosis". The Cochrane Database of Systematic Reviews. 12 (12) CD000551. doi:10.1002/14651858.CD000551.pub3. PMC 7045744. PMID 23235576.
Bowlus CL, Kenney JT, Rice G, Navarro R (October 2016). "Primary Biliary Cholangitis: Medical and Specialty Pharmacy Management Update". Journal of Managed Care & Specialty Pharmacy. 22 (10-a-s Suppl): S3 – S15. doi:10.18553/jmcp.2016.22.10-a-s.s3. PMC 10408407. PMID 27700211.
Poropat G, Giljaca V, Stimac D, Gluud C (January 2011). "Bile acids for primary sclerosing cholangitis". The Cochrane Database of Systematic Reviews. 2011 (1) CD003626. doi:10.1002/14651858.CD003626.pub2. PMC 7163275. PMID 21249655.
Lindor KD, Kowdley KV, Luketic VA, Harrison ME, McCashland T, Befeler AS, et al. (September 2009). "High-dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis". Hepatology. 50 (3): 808–814. doi:10.1002/hep.23082. PMC 2758780. PMID 19585548.
Walker KF, Chappell LC, Hague WM, Middleton P, Thornton JG (July 2020). "Pharmacological interventions for treating intrahepatic cholestasis of pregnancy". The Cochrane Database of Systematic Reviews. 2020 (7) CD000493. doi:10.1002/14651858.CD000493.pub3. PMC 7389072. PMID 32716060.
Chappell LC, Bell JL, Smith A, Linsell L, Juszczak E, Dixon PH, et al. (September 2019). "Ursodeoxycholic acid versus placebo in women with intrahepatic cholestasis of pregnancy (PITCHES): a randomised controlled trial". Lancet. 394 (10201): 849–860. doi:10.1016/S0140-6736(19)31270-X. PMC 6739598. PMID 31378395.
Kotb MA (July 2008). "Review of historical cohort: ursodeoxycholic acid in extrahepatic biliary atresia". Journal of Pediatric Surgery. 43 (7): 1321–1327. doi:10.1016/j.jpedsurg.2007.11.043. PMID 18639689.
Kotb MA, Mosallam D, Basanti CW, El Sorogy ST, Badr AM, Abd El Baky HE, et al. (February 2020). "Ursodeoxycholic acid use is associated with significant risk of morbidity and mortality in infants with cholestasis: A strobe compliant study". Medicine. 99 (7) e18730. doi:10.1097/MD.0000000000018730. PMC 7035015. PMID 32049781.
McCabe ME, Dilly CK (September 2018). "New Causes for the Old Problem of Bile Reflux Gastritis". Clinical Gastroenterology and Hepatology. 16 (9): 1389–1392. doi:10.1016/j.cgh.2018.02.034. hdl:1805/15771. PMID 29505908. S2CID 3748071.
Colombo C, Alicandro G, Oliver M, Lewindon PJ, Ramm GA, Ooi CY, et al. (March 2022). "Ursodeoxycholic acid and liver disease associated with cystic fibrosis: A multicenter cohort study". Journal of Cystic Fibrosis. 21 (2): 220–226. doi:10.1016/j.jcf.2021.03.014. PMID 33814323.
Hempfling W, Dilger K, Beuers U (November 2003). "Systematic review: ursodeoxycholic acid--adverse effects and drug interactions". Alimentary Pharmacology & Therapeutics. 18 (10): 963–972. doi:10.1046/j.1365-2036.2003.01792.x. PMID 14616161. S2CID 25738560.
Lleo A, Wang GQ, Gershwin ME, Hirschfield GM (December 2020). "Primary biliary cholangitis". Lancet. 396 (10266): 1915–1926. doi:10.1016/S0140-6736(20)31607-X. PMID 33308474. S2CID 228086916.
Tint GS, Salen G, Shefer S (October 1986). "Effect of ursodeoxycholic acid and chenodeoxycholic acid on cholesterol and bile acid metabolism". Gastroenterology. 91 (4): 1007–1018. doi:10.1016/0016-5085(86)90708-0. PMID 3527851.
Paumgartner G, Beuers U (September 2002). "Ursodeoxycholic acid in cholestatic liver disease: mechanisms of action and therapeutic use revisited". Hepatology. 36 (3): 525–531. doi:10.1053/jhep.2002.36088. PMID 12198643. S2CID 28282761.
Ward JB, Lajczak NK, Kelly OB, O'Dwyer AM, Giddam AK, Ní Gabhann J, et al. (June 2017). "Ursodeoxycholic acid and lithocholic acid exert anti-inflammatory actions in the colon". American Journal of Physiology. Gastrointestinal and Liver Physiology. 312 (6): G550–8. doi:10.1152/ajpgi.00256.2016. PMID 28360029.
Lajczak NK, Saint-Criq V, O'Dwyer AM, Perino A, Adorini L, Schoonjans K, et al. (September 2017). "Bile acids deoxycholic acid and ursodeoxycholic acid differentially regulate human β-defensin-1 and -2 secretion by colonic epithelial cells". FASEB Journal. 31 (9): 3848–57. doi:10.1096/fj.201601365R. PMID 28487283. S2CID 46877147.
Mroz MS, Lajczak NK, Goggins BJ, Keely S, Keely SJ (March 2018). "The bile acids, deoxycholic acid and ursodeoxycholic acid, regulate colonic epithelial wound healing". American Journal of Physiology. Gastrointestinal and Liver Physiology. 314 (3): G378–87. doi:10.1152/ajpgi.00435.2016. PMID 29351391. S2CID 3767047.
O'Dwyer AM, Lajczak NK, Keyes JA, Ward JB, Greene CM, Keely SJ (August 2016). "Ursodeoxycholic acid inhibits TNFα-induced IL-8 release from monocytes". American Journal of Physiology. Gastrointestinal and Liver Physiology. 311 (2): G334–41. doi:10.1152/ajpgi.00406.2015. PMID 27340129.
Fogelson KA, Dorrestein PC, Zarrinpar A, Knight R (June 2023). "The Gut Microbial Bile Acid Modulation and Its Relevance to Digestive Health and Diseases". Gastroenterology. 164 (7): 1069–85. doi:10.1053/j.gastro.2023.02.022. PMC 10205675. PMID 36841488.
Bernstein H, Bernstein C (January 2023). "Bile acids as carcinogens in the colon and at other sites in the gastrointestinal system". Exp Biol Med (Maywood). 248 (1): 79–89. doi:10.1177/15353702221131858. PMC 9989147. PMID 36408538.
Yang S, Wang Y, Sheng L, Cui W, Ma C (January 2025). "The effect of fecal bile acids on the incidence and risk-stratification of colorectal cancer: an updated systematic review and meta-analysis". Sci Rep. 15 (1): 740. Bibcode:2025NatSR..15..740Y. doi:10.1038/s41598-024-84801-6. PMC 11698987. PMID 39753873.
Akare S, Jean-Louis S, Chen W, Wood DJ, Powell AA, Martinez JD (December 2006). "Ursodeoxycholic acid modulates histone acetylation and induces differentiation and senescence". International Journal of Cancer. 119 (12): 2958–69. doi:10.1002/ijc.22231. PMID 17019713. S2CID 21187798.
Kühn T, Stepien M, López-Nogueroles M, Damms-Machado A, Sookthai D, Johnson T, et al. (May 2020). "Prediagnostic Plasma Bile Acid Levels and Colon Cancer Risk: A Prospective Study". J Natl Cancer Inst. 112 (5): 516–524. doi:10.1093/jnci/djz166. PMC 7225675. PMID 31435679.
Alberts DS, Martínez ME, Hess LM, Einspahr JG, Green SB, Bhattacharyya AK, et al. (June 2005). "Phase III trial of ursodeoxycholic acid to prevent colorectal adenoma recurrence". J Natl Cancer Inst. 97 (11): 846–53. doi:10.1093/jnci/dji144. PMID 15928305.
Feng Y, Siu K, Wang N, Ng KM, Tsao SW, Nagamatsu T, et al. (January 2009). "Bear bile: dilemma of traditional medicinal use and animal protection". Journal of Ethnobiology and Ethnomedicine. 5 (1): 2. doi:10.1186/1746-4269-5-2. PMC 2630947. PMID 19138420.
Devlin AS, Fischbach MA (September 2015). "A biosynthetic pathway for a prominent class of microbiota-derived bile acids". Nature Chemical Biology. 11 (9): 685–690. doi:10.1038/nchembio.1864. PMC 4543561. PMID 26192599.
Tonin F, Arends IW (2018). "Latest development in the synthesis of ursodeoxycholic acid (UDCA): a critical review". Beilstein Journal of Organic Chemistry. 14: 470–483. doi:10.3762/bjoc.14.33. PMC 5827811. PMID 29520309.
Arakawa T, Kagaya A, Inaba Y (September 1957). "Ursodesoxycholic acid as in accelerator for riboflavin phosphorylation in children with nutritional dystrophy". The Journal of Vitaminology. 3 (3): 165–167. doi:10.5925/jnsv1954.3.165. PMID 13476545.

drugs.com (Global: 399^th place; English: 333^rd place)

"Ursodiol, Heptiza 300/150 Use During Pregnancy". Drugs.com. 4 November 2019. Retrieved 20 February 2020.

fda.gov (Global: 447^th place; English: 338^th place)

accessdata.fda.gov

"Ursodiol: FDA-Approved Drugs". U.S. Food and Drug Administration (FDA). Retrieved 25 September 2021.
"Actigall: FDA-Approved Drugs". U.S. Food and Drug Administration (FDA). Archived from the original on 25 January 2017. Retrieved 29 April 2020.
"Actigall Orphan Drug Designation and Approval". U.S. Food and Drug Administration (FDA). Archived from the original on 9 August 2020. Retrieved 29 April 2020.

fda.gov

"2020 First Generic Drug Approvals". U.S. Food and Drug Administration (FDA). 23 February 2021. Archived from the original on 17 May 2021. Retrieved 25 September 2021.

fishersci.com (Global: low place; English: low place)

fscimage.fishersci.com

"Ursodiol". Material Safety Data Sheet (MSDS). Fisher Scientific. Archived from the original on 13 October 2011. Retrieved 12 March 2010.

handle.net (Global: 102^nd place; English: 76^th place)

hdl.handle.net

McCabe ME, Dilly CK (September 2018). "New Causes for the Old Problem of Bile Reflux Gastritis". Clinical Gastroenterology and Hepatology. 16 (9): 1389–1392. doi:10.1016/j.cgh.2018.02.034. hdl:1805/15771. PMID 29505908. S2CID 3748071.

harvard.edu (Global: 18^th place; English: 17^th place)

ui.adsabs.harvard.edu

Yang S, Wang Y, Sheng L, Cui W, Ma C (January 2025). "The effect of fecal bile acids on the incidence and risk-stratification of colorectal cancer: an updated systematic review and meta-analysis". Sci Rep. 15 (1): 740. Bibcode:2025NatSR..15..740Y. doi:10.1038/s41598-024-84801-6. PMC 11698987. PMID 39753873.

hpfb-dgpsa.ca (Global: low place; English: low place)

dhpp.hpfb-dgpsa.ca

"Details for: Ursodiol C". Health Canada. 25 October 2021. Retrieved 3 March 2024.

medicines.org.uk (Global: 3,823^rd place; English: 2,387^th place)

"Ursodeoxycholic acid 300mg Tablets - Summary of Product Characteristics (SmPC)". (emc). 10 July 2019. Retrieved 29 April 2020.

nih.gov (Global: 4^th place; English: 4^th place)

pubmed.ncbi.nlm.nih.gov

Hagey LR, Crombie DL, Espinosa E, Carey MC, Igimi H, Hofmann AF (November 1993). "Ursodeoxycholic acid in the Ursidae: biliary bile acids of bears, pandas, and related carnivores". Journal of Lipid Research. 34 (11): 1911–1917. doi:10.1016/S0022-2275(20)35109-9. PMID 8263415.
Hofmann AF (September 1989). "Medical dissolution of gallstones by oral bile acid therapy". American Journal of Surgery. 158 (3): 198–204. doi:10.1016/0002-9610(89)90252-3. PMID 2672842.
Jüngst C, Kullak-Ublick GA, Jüngst D (2006). "Gallstone disease: Microlithiasis and sludge". Best Practice & Research. Clinical Gastroenterology. 20 (6): 1053–1062. doi:10.1016/j.bpg.2006.03.007. PMID 17127187.
Magouliotis DE, Tasiopoulou VS, Svokos AA, Svokos KA, Chatedaki C, Sioka E, et al. (November 2017). "Ursodeoxycholic Acid in the Prevention of Gallstone Formation After Bariatric Surgery: an Updated Systematic Review and Meta-analysis". Obesity Surgery. 27 (11): 3021–3030. doi:10.1007/s11695-017-2924-y. PMID 28889240. S2CID 4622165.
Poupon RE, Balkau B, Eschwège E, Poupon R (May 1991). "A multicenter, controlled trial of ursodiol for the treatment of primary biliary cirrhosis. UDCA-PBC Study Group". The New England Journal of Medicine. 324 (22): 1548–1554. doi:10.1056/NEJM199105303242204. PMID 1674105.
Goulis J, Leandro G, Burroughs AK (September 1999). "Randomised controlled trials of ursodeoxycholic-acid therapy for primary biliary cirrhosis: a meta-analysis". Lancet. 354 (9184): 1053–1060. doi:10.1016/S0140-6736(98)11293-X. PMID 10509495. S2CID 25562983.
Shi J, Wu C, Lin Y, Chen YX, Zhu L, Xie WF (July 2006). "Long-term effects of mid-dose ursodeoxycholic acid in primary biliary cirrhosis: a meta-analysis of randomized controlled trials". The American Journal of Gastroenterology. 101 (7): 1529–1538. doi:10.1111/j.1572-0241.2006.00634.x. PMID 16863557. S2CID 32076958.
Rudic JS, Poropat G, Krstic MN, Bjelakovic G, Gluud C (December 2012). "Ursodeoxycholic acid for primary biliary cirrhosis". The Cochrane Database of Systematic Reviews. 12 (12) CD000551. doi:10.1002/14651858.CD000551.pub3. PMC 7045744. PMID 23235576.
Bowlus CL, Kenney JT, Rice G, Navarro R (October 2016). "Primary Biliary Cholangitis: Medical and Specialty Pharmacy Management Update". Journal of Managed Care & Specialty Pharmacy. 22 (10-a-s Suppl): S3 – S15. doi:10.18553/jmcp.2016.22.10-a-s.s3. PMC 10408407. PMID 27700211.
Poropat G, Giljaca V, Stimac D, Gluud C (January 2011). "Bile acids for primary sclerosing cholangitis". The Cochrane Database of Systematic Reviews. 2011 (1) CD003626. doi:10.1002/14651858.CD003626.pub2. PMC 7163275. PMID 21249655.
Lindor KD, Kowdley KV, Luketic VA, Harrison ME, McCashland T, Befeler AS, et al. (September 2009). "High-dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis". Hepatology. 50 (3): 808–814. doi:10.1002/hep.23082. PMC 2758780. PMID 19585548.
Walker KF, Chappell LC, Hague WM, Middleton P, Thornton JG (July 2020). "Pharmacological interventions for treating intrahepatic cholestasis of pregnancy". The Cochrane Database of Systematic Reviews. 2020 (7) CD000493. doi:10.1002/14651858.CD000493.pub3. PMC 7389072. PMID 32716060.
Chappell LC, Bell JL, Smith A, Linsell L, Juszczak E, Dixon PH, et al. (September 2019). "Ursodeoxycholic acid versus placebo in women with intrahepatic cholestasis of pregnancy (PITCHES): a randomised controlled trial". Lancet. 394 (10201): 849–860. doi:10.1016/S0140-6736(19)31270-X. PMC 6739598. PMID 31378395.
Kotb MA (July 2008). "Review of historical cohort: ursodeoxycholic acid in extrahepatic biliary atresia". Journal of Pediatric Surgery. 43 (7): 1321–1327. doi:10.1016/j.jpedsurg.2007.11.043. PMID 18639689.
Kotb MA, Mosallam D, Basanti CW, El Sorogy ST, Badr AM, Abd El Baky HE, et al. (February 2020). "Ursodeoxycholic acid use is associated with significant risk of morbidity and mortality in infants with cholestasis: A strobe compliant study". Medicine. 99 (7) e18730. doi:10.1097/MD.0000000000018730. PMC 7035015. PMID 32049781.
McCabe ME, Dilly CK (September 2018). "New Causes for the Old Problem of Bile Reflux Gastritis". Clinical Gastroenterology and Hepatology. 16 (9): 1389–1392. doi:10.1016/j.cgh.2018.02.034. hdl:1805/15771. PMID 29505908. S2CID 3748071.
Colombo C, Alicandro G, Oliver M, Lewindon PJ, Ramm GA, Ooi CY, et al. (March 2022). "Ursodeoxycholic acid and liver disease associated with cystic fibrosis: A multicenter cohort study". Journal of Cystic Fibrosis. 21 (2): 220–226. doi:10.1016/j.jcf.2021.03.014. PMID 33814323.
Hempfling W, Dilger K, Beuers U (November 2003). "Systematic review: ursodeoxycholic acid--adverse effects and drug interactions". Alimentary Pharmacology & Therapeutics. 18 (10): 963–972. doi:10.1046/j.1365-2036.2003.01792.x. PMID 14616161. S2CID 25738560.
Lleo A, Wang GQ, Gershwin ME, Hirschfield GM (December 2020). "Primary biliary cholangitis". Lancet. 396 (10266): 1915–1926. doi:10.1016/S0140-6736(20)31607-X. PMID 33308474. S2CID 228086916.
Tint GS, Salen G, Shefer S (October 1986). "Effect of ursodeoxycholic acid and chenodeoxycholic acid on cholesterol and bile acid metabolism". Gastroenterology. 91 (4): 1007–1018. doi:10.1016/0016-5085(86)90708-0. PMID 3527851.
Paumgartner G, Beuers U (September 2002). "Ursodeoxycholic acid in cholestatic liver disease: mechanisms of action and therapeutic use revisited". Hepatology. 36 (3): 525–531. doi:10.1053/jhep.2002.36088. PMID 12198643. S2CID 28282761.
Ward JB, Lajczak NK, Kelly OB, O'Dwyer AM, Giddam AK, Ní Gabhann J, et al. (June 2017). "Ursodeoxycholic acid and lithocholic acid exert anti-inflammatory actions in the colon". American Journal of Physiology. Gastrointestinal and Liver Physiology. 312 (6): G550–8. doi:10.1152/ajpgi.00256.2016. PMID 28360029.
Lajczak NK, Saint-Criq V, O'Dwyer AM, Perino A, Adorini L, Schoonjans K, et al. (September 2017). "Bile acids deoxycholic acid and ursodeoxycholic acid differentially regulate human β-defensin-1 and -2 secretion by colonic epithelial cells". FASEB Journal. 31 (9): 3848–57. doi:10.1096/fj.201601365R. PMID 28487283. S2CID 46877147.
Mroz MS, Lajczak NK, Goggins BJ, Keely S, Keely SJ (March 2018). "The bile acids, deoxycholic acid and ursodeoxycholic acid, regulate colonic epithelial wound healing". American Journal of Physiology. Gastrointestinal and Liver Physiology. 314 (3): G378–87. doi:10.1152/ajpgi.00435.2016. PMID 29351391. S2CID 3767047.
O'Dwyer AM, Lajczak NK, Keyes JA, Ward JB, Greene CM, Keely SJ (August 2016). "Ursodeoxycholic acid inhibits TNFα-induced IL-8 release from monocytes". American Journal of Physiology. Gastrointestinal and Liver Physiology. 311 (2): G334–41. doi:10.1152/ajpgi.00406.2015. PMID 27340129.
Fogelson KA, Dorrestein PC, Zarrinpar A, Knight R (June 2023). "The Gut Microbial Bile Acid Modulation and Its Relevance to Digestive Health and Diseases". Gastroenterology. 164 (7): 1069–85. doi:10.1053/j.gastro.2023.02.022. PMC 10205675. PMID 36841488.
Bernstein H, Bernstein C (January 2023). "Bile acids as carcinogens in the colon and at other sites in the gastrointestinal system". Exp Biol Med (Maywood). 248 (1): 79–89. doi:10.1177/15353702221131858. PMC 9989147. PMID 36408538.
Yang S, Wang Y, Sheng L, Cui W, Ma C (January 2025). "The effect of fecal bile acids on the incidence and risk-stratification of colorectal cancer: an updated systematic review and meta-analysis". Sci Rep. 15 (1): 740. Bibcode:2025NatSR..15..740Y. doi:10.1038/s41598-024-84801-6. PMC 11698987. PMID 39753873.
Akare S, Jean-Louis S, Chen W, Wood DJ, Powell AA, Martinez JD (December 2006). "Ursodeoxycholic acid modulates histone acetylation and induces differentiation and senescence". International Journal of Cancer. 119 (12): 2958–69. doi:10.1002/ijc.22231. PMID 17019713. S2CID 21187798.
Kühn T, Stepien M, López-Nogueroles M, Damms-Machado A, Sookthai D, Johnson T, et al. (May 2020). "Prediagnostic Plasma Bile Acid Levels and Colon Cancer Risk: A Prospective Study". J Natl Cancer Inst. 112 (5): 516–524. doi:10.1093/jnci/djz166. PMC 7225675. PMID 31435679.
Alberts DS, Martínez ME, Hess LM, Einspahr JG, Green SB, Bhattacharyya AK, et al. (June 2005). "Phase III trial of ursodeoxycholic acid to prevent colorectal adenoma recurrence". J Natl Cancer Inst. 97 (11): 846–53. doi:10.1093/jnci/dji144. PMID 15928305.
Feng Y, Siu K, Wang N, Ng KM, Tsao SW, Nagamatsu T, et al. (January 2009). "Bear bile: dilemma of traditional medicinal use and animal protection". Journal of Ethnobiology and Ethnomedicine. 5 (1): 2. doi:10.1186/1746-4269-5-2. PMC 2630947. PMID 19138420.
Devlin AS, Fischbach MA (September 2015). "A biosynthetic pathway for a prominent class of microbiota-derived bile acids". Nature Chemical Biology. 11 (9): 685–690. doi:10.1038/nchembio.1864. PMC 4543561. PMID 26192599.
Tonin F, Arends IW (2018). "Latest development in the synthesis of ursodeoxycholic acid (UDCA): a critical review". Beilstein Journal of Organic Chemistry. 14: 470–483. doi:10.3762/bjoc.14.33. PMC 5827811. PMID 29520309.
Arakawa T, Kagaya A, Inaba Y (September 1957). "Ursodesoxycholic acid as in accelerator for riboflavin phosphorylation in children with nutritional dystrophy". The Journal of Vitaminology. 3 (3): 165–167. doi:10.5925/jnsv1954.3.165. PMID 13476545.

ncbi.nlm.nih.gov

Rudic JS, Poropat G, Krstic MN, Bjelakovic G, Gluud C (December 2012). "Ursodeoxycholic acid for primary biliary cirrhosis". The Cochrane Database of Systematic Reviews. 12 (12) CD000551. doi:10.1002/14651858.CD000551.pub3. PMC 7045744. PMID 23235576.
Bowlus CL, Kenney JT, Rice G, Navarro R (October 2016). "Primary Biliary Cholangitis: Medical and Specialty Pharmacy Management Update". Journal of Managed Care & Specialty Pharmacy. 22 (10-a-s Suppl): S3 – S15. doi:10.18553/jmcp.2016.22.10-a-s.s3. PMC 10408407. PMID 27700211.
Poropat G, Giljaca V, Stimac D, Gluud C (January 2011). "Bile acids for primary sclerosing cholangitis". The Cochrane Database of Systematic Reviews. 2011 (1) CD003626. doi:10.1002/14651858.CD003626.pub2. PMC 7163275. PMID 21249655.
Lindor KD, Kowdley KV, Luketic VA, Harrison ME, McCashland T, Befeler AS, et al. (September 2009). "High-dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis". Hepatology. 50 (3): 808–814. doi:10.1002/hep.23082. PMC 2758780. PMID 19585548.
Walker KF, Chappell LC, Hague WM, Middleton P, Thornton JG (July 2020). "Pharmacological interventions for treating intrahepatic cholestasis of pregnancy". The Cochrane Database of Systematic Reviews. 2020 (7) CD000493. doi:10.1002/14651858.CD000493.pub3. PMC 7389072. PMID 32716060.
Chappell LC, Bell JL, Smith A, Linsell L, Juszczak E, Dixon PH, et al. (September 2019). "Ursodeoxycholic acid versus placebo in women with intrahepatic cholestasis of pregnancy (PITCHES): a randomised controlled trial". Lancet. 394 (10201): 849–860. doi:10.1016/S0140-6736(19)31270-X. PMC 6739598. PMID 31378395.
Kotb MA, Mosallam D, Basanti CW, El Sorogy ST, Badr AM, Abd El Baky HE, et al. (February 2020). "Ursodeoxycholic acid use is associated with significant risk of morbidity and mortality in infants with cholestasis: A strobe compliant study". Medicine. 99 (7) e18730. doi:10.1097/MD.0000000000018730. PMC 7035015. PMID 32049781.
Fogelson KA, Dorrestein PC, Zarrinpar A, Knight R (June 2023). "The Gut Microbial Bile Acid Modulation and Its Relevance to Digestive Health and Diseases". Gastroenterology. 164 (7): 1069–85. doi:10.1053/j.gastro.2023.02.022. PMC 10205675. PMID 36841488.
Bernstein H, Bernstein C (January 2023). "Bile acids as carcinogens in the colon and at other sites in the gastrointestinal system". Exp Biol Med (Maywood). 248 (1): 79–89. doi:10.1177/15353702221131858. PMC 9989147. PMID 36408538.
Yang S, Wang Y, Sheng L, Cui W, Ma C (January 2025). "The effect of fecal bile acids on the incidence and risk-stratification of colorectal cancer: an updated systematic review and meta-analysis". Sci Rep. 15 (1): 740. Bibcode:2025NatSR..15..740Y. doi:10.1038/s41598-024-84801-6. PMC 11698987. PMID 39753873.
Kühn T, Stepien M, López-Nogueroles M, Damms-Machado A, Sookthai D, Johnson T, et al. (May 2020). "Prediagnostic Plasma Bile Acid Levels and Colon Cancer Risk: A Prospective Study". J Natl Cancer Inst. 112 (5): 516–524. doi:10.1093/jnci/djz166. PMC 7225675. PMID 31435679.
Feng Y, Siu K, Wang N, Ng KM, Tsao SW, Nagamatsu T, et al. (January 2009). "Bear bile: dilemma of traditional medicinal use and animal protection". Journal of Ethnobiology and Ethnomedicine. 5 (1): 2. doi:10.1186/1746-4269-5-2. PMC 2630947. PMID 19138420.
Devlin AS, Fischbach MA (September 2015). "A biosynthetic pathway for a prominent class of microbiota-derived bile acids". Nature Chemical Biology. 11 (9): 685–690. doi:10.1038/nchembio.1864. PMC 4543561. PMID 26192599.
Tonin F, Arends IW (2018). "Latest development in the synthesis of ursodeoxycholic acid (UDCA): a critical review". Beilstein Journal of Organic Chemistry. 14: 470–483. doi:10.3762/bjoc.14.33. PMC 5827811. PMID 29520309.

dailymed.nlm.nih.gov

"Actigall (ursodiol, USP) capsules". DailyMed. Retrieved 25 September 2021.
"Urso 250- ursodiol tablet, film coated Urso Forte- ursodiol tablet, film coated". DailyMed. Retrieved 25 September 2021.

pubchem.ncbi.nlm.nih.gov

"Ursodiol". PubChem. U.S. National Library of Medicine.

semanticscholar.org (Global: 11^th place; English: 8^th place)

api.semanticscholar.org

Magouliotis DE, Tasiopoulou VS, Svokos AA, Svokos KA, Chatedaki C, Sioka E, et al. (November 2017). "Ursodeoxycholic Acid in the Prevention of Gallstone Formation After Bariatric Surgery: an Updated Systematic Review and Meta-analysis". Obesity Surgery. 27 (11): 3021–3030. doi:10.1007/s11695-017-2924-y. PMID 28889240. S2CID 4622165.
Goulis J, Leandro G, Burroughs AK (September 1999). "Randomised controlled trials of ursodeoxycholic-acid therapy for primary biliary cirrhosis: a meta-analysis". Lancet. 354 (9184): 1053–1060. doi:10.1016/S0140-6736(98)11293-X. PMID 10509495. S2CID 25562983.
Shi J, Wu C, Lin Y, Chen YX, Zhu L, Xie WF (July 2006). "Long-term effects of mid-dose ursodeoxycholic acid in primary biliary cirrhosis: a meta-analysis of randomized controlled trials". The American Journal of Gastroenterology. 101 (7): 1529–1538. doi:10.1111/j.1572-0241.2006.00634.x. PMID 16863557. S2CID 32076958.
McCabe ME, Dilly CK (September 2018). "New Causes for the Old Problem of Bile Reflux Gastritis". Clinical Gastroenterology and Hepatology. 16 (9): 1389–1392. doi:10.1016/j.cgh.2018.02.034. hdl:1805/15771. PMID 29505908. S2CID 3748071.
Hempfling W, Dilger K, Beuers U (November 2003). "Systematic review: ursodeoxycholic acid--adverse effects and drug interactions". Alimentary Pharmacology & Therapeutics. 18 (10): 963–972. doi:10.1046/j.1365-2036.2003.01792.x. PMID 14616161. S2CID 25738560.
Lleo A, Wang GQ, Gershwin ME, Hirschfield GM (December 2020). "Primary biliary cholangitis". Lancet. 396 (10266): 1915–1926. doi:10.1016/S0140-6736(20)31607-X. PMID 33308474. S2CID 228086916.
Paumgartner G, Beuers U (September 2002). "Ursodeoxycholic acid in cholestatic liver disease: mechanisms of action and therapeutic use revisited". Hepatology. 36 (3): 525–531. doi:10.1053/jhep.2002.36088. PMID 12198643. S2CID 28282761.
Lajczak NK, Saint-Criq V, O'Dwyer AM, Perino A, Adorini L, Schoonjans K, et al. (September 2017). "Bile acids deoxycholic acid and ursodeoxycholic acid differentially regulate human β-defensin-1 and -2 secretion by colonic epithelial cells". FASEB Journal. 31 (9): 3848–57. doi:10.1096/fj.201601365R. PMID 28487283. S2CID 46877147.
Mroz MS, Lajczak NK, Goggins BJ, Keely S, Keely SJ (March 2018). "The bile acids, deoxycholic acid and ursodeoxycholic acid, regulate colonic epithelial wound healing". American Journal of Physiology. Gastrointestinal and Liver Physiology. 314 (3): G378–87. doi:10.1152/ajpgi.00435.2016. PMID 29351391. S2CID 3767047.
Akare S, Jean-Louis S, Chen W, Wood DJ, Powell AA, Martinez JD (December 2006). "Ursodeoxycholic acid modulates histone acetylation and induces differentiation and senescence". International Journal of Cancer. 119 (12): 2958–69. doi:10.1002/ijc.22231. PMID 17019713. S2CID 21187798.

sukl.cz (Global: low place; English: low place)

prehledy.sukl.cz

"Ursofalk". Registered LP name (in Czech). Prague, Czech Republic: State Institute for Drug Control.

tga.gov.au (Global: 3,984^th place; English: 2,622^nd place)

"Prescription medicines: registration of new generic medicines and biosimilar medicines, 2017". Therapeutic Goods Administration (TGA). 21 June 2022. Retrieved 30 March 2024.

web.archive.org (Global: 1^st place; English: 1^st place)

"2020 First Generic Drug Approvals". U.S. Food and Drug Administration (FDA). 23 February 2021. Archived from the original on 17 May 2021. Retrieved 25 September 2021.
"Urso package insert" (PDF). Birmingham, AL: Axcan Pharma U.S. January 2000. Archived from the original (PDF) on 17 October 2006. Retrieved 25 April 2009.
"Ursodiol". Material Safety Data Sheet (MSDS). Fisher Scientific. Archived from the original on 13 October 2011. Retrieved 12 March 2010.
"Actigall: FDA-Approved Drugs". U.S. Food and Drug Administration (FDA). Archived from the original on 25 January 2017. Retrieved 29 April 2020.
"Actigall Orphan Drug Designation and Approval". U.S. Food and Drug Administration (FDA). Archived from the original on 9 August 2020. Retrieved 29 April 2020.

who.int (Global: 195^th place; English: 302^nd place)

"Ursodeoxycholic acid: serious hepatic events" (PDF). WHO Drug Information. 26 (1). 2012.

Ursodeoxycholic acid (English Wikipedia)

axcan.com (Global: low place; English: low place)

canada.ca (Global: 1,712th place; English: 1,063rd place)

health-products.canada.ca

doi.org (Global: 2nd place; English: 2nd place)

drugs.com (Global: 399th place; English: 333rd place)

fda.gov (Global: 447th place; English: 338th place)

accessdata.fda.gov

fda.gov

fishersci.com (Global: low place; English: low place)

fscimage.fishersci.com

handle.net (Global: 102nd place; English: 76th place)

hdl.handle.net

harvard.edu (Global: 18th place; English: 17th place)

ui.adsabs.harvard.edu

hpfb-dgpsa.ca (Global: low place; English: low place)

dhpp.hpfb-dgpsa.ca

medicines.org.uk (Global: 3,823rd place; English: 2,387th place)

nih.gov (Global: 4th place; English: 4th place)

pubmed.ncbi.nlm.nih.gov

ncbi.nlm.nih.gov

dailymed.nlm.nih.gov

pubchem.ncbi.nlm.nih.gov

semanticscholar.org (Global: 11th place; English: 8th place)

api.semanticscholar.org

sukl.cz (Global: low place; English: low place)

prehledy.sukl.cz

tga.gov.au (Global: 3,984th place; English: 2,622nd place)

web.archive.org (Global: 1st place; English: 1st place)

who.int (Global: 195th place; English: 302nd place)

canada.ca (Global: 1,712^th place; English: 1,063^rd place)

doi.org (Global: 2^nd place; English: 2^nd place)

drugs.com (Global: 399^th place; English: 333^rd place)

fda.gov (Global: 447^th place; English: 338^th place)

handle.net (Global: 102^nd place; English: 76^th place)

harvard.edu (Global: 18^th place; English: 17^th place)

medicines.org.uk (Global: 3,823^rd place; English: 2,387^th place)

nih.gov (Global: 4^th place; English: 4^th place)

semanticscholar.org (Global: 11^th place; English: 8^th place)

tga.gov.au (Global: 3,984^th place; English: 2,622^nd place)

web.archive.org (Global: 1^st place; English: 1^st place)

who.int (Global: 195^th place; English: 302^nd place)